Poolbeg Pharma patent opposition to be withdrawn

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that the opposition to one of its European patents (Immunomodulator I) that was previously filed by a third party is to be withdrawn.

In the pharmaceutical industry it is not unusual for patents to be challenged. The Immunomodulator I European patent was opposed by a third party in September 2021. Further to engaging with the opposing party, Poolbeg has reached an amicable conclusion in relation to the patent dispute without any financial compensation between the parties. This has resulted in the opposing party agreeing to withdraw its opposition to the Immunomodulator I European patent and agreeing not to challenge any of Poolbeg’s Immunomodulator I or Immunomodulator II patents in the future.

The Company will be communicating with the European Patent Office (‘EPO’) regarding the necessity of continuing with the scheduled hearing in November. Based on specialist advice received, and the fact that the patent went through an extensive examination process prior to being granted by the EPO, Poolbeg continues to have full confidence in the validity and strength of the patent and will defend its intellectual property to the extent required.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma

The growing role of AI in drug discovery

Bringing a new drug to market is an enormously complex and expensive process, often taking over a decade and costing upwards of $2 billion. The pharmaceutical industry faces increasing pressure to improve R&D productivity and efficiency. Artificial intelligence

Poolbeg Pharma

Poolbeg Pharma gets go-ahead for Japanese patent

Dublin-based infectious disease specialist Poolbeg Pharma has received a green light from Japan’s patent office, relating to a patent application for the company’s “potential blockbuster treatment” for severe influenza. The Japanese Patent Office has issued a notice of

Poolbeg Pharma

AI Unleashed: Experts from Poolbeg Pharma & CytoReason

Roundtable discussion featuring Artificial Intelligence hot topics, such as: The future of AI How AI could have contributed to the COVID-19 pandemic Highlights from the exciting collaboration between Poolbeg Pharma and CytoReason. Speakers: Jeremy Skillington – CEO of

Poolbeg Pharma

Poolbeg Pharma plc granted allowance from the Japanese Patent Office

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent application. The

Poolbeg Pharma

AI to revolutionise drug development by 2026

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development, within the

Poolbeg Pharma

Poolbeg Pharma make significant progress in advancing pipeline

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2023. Interim Results Highlights and Business Update ·    Strong cash balance

Poolbeg Pharma

Poolbeg Pharma’s Oral Vaccine Platform

By delivering vaccines to the gut, oral vaccines can trigger ‘mucosal immunity’ which prevents pathogens infecting the body by producing a protective response in the areas of the body where there is a high level of infectious threat,

Poolbeg Pharma

AI Unleashed: Featuring Experts from Poolbeg Pharma & CytoReason

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma

The potential benefits of AI in the development of medicines

Warnings about the potential threats of artificial intelligence (AI) technology have been coming from various industries. However, one of Britain’s largest drug firms, GlaxoSmithKline (GSK), believes that the use of cutting-edge AI could have a positive impact on

Poolbeg Pharma

AI will be a game-changer for medicine

Warnings about the potential threats of artificial intelligence (AI) technology have been coming thick and fast from a wide range of industries. But the use of cutting-edge AI could benefit us all by dramatically speeding up the development

Poolbeg Pharma

The role of generative AI in drug discovery

The field of drug discovery is challenging and time-consuming, but generative artificial intelligence (AI) has the potential to revolutionize this process. Generative AI, a subfield of AI, focuses on creating new data instances that resemble existing data. In

Poolbeg Pharma

How is AI transforming drug discovery?

The emergence of AI, notably in the field of drug discovery, is reshaping the future of medicine The emergence of artificial intelligence (AI), notably in the field of drug discovery, is reshaping the future of medicine. The pharmaceutical business is

No more posts to show